Olaparib and bevacizumab in front-line maintenance of ovarian cancer: an over reliance in unpowered subgroup analysis of the PAOLA-1 trial?
Sign Up to like & getrecommendations! Published in 2020 at "Journal of Gynecologic Oncology"
DOI: 10.3802/jgo.2020.31.e95
Abstract: https://ejgo.org Epithelial ovarian cancer (EOC) is usually diagnosed as a locally advanced disease (International Federation of Gynecology and Obstetrics 2018 stages III/IV) and is the most lethal gynecological cancer in developed countries [1]. Primary treatment… read more here.
Keywords: bevacizumab front; front line; ovarian cancer; line maintenance ... See more keywords